Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 20Leukemia, Myeloid, Acute 8Recurrence 7Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Thymoma 2Ovarian Neoplasms 2Carcinoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Richter's Transformation 1Rhabdoid Tumor 1Prostatic Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1MDS 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Everolimus 9Cisplatin 8Temozolomide 6Nivolumab 5Etoposide 5Carboplatin 5Bevacizumab 5lutetium Lu 177 dotatate 4Capecitabine 4pembrolizumab 3Irinotecan 3sintilimab 2dostarlimab 2cabozantinib 2azaspirane 2avelumab 2atezolizumab 2Paclitaxel 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Ipilimumab 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2zimberelimab 1surufatinib 1selinexor 1pertuzumab 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Neuroendocrine × selinexor × Clear all
NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Gabrail Cancer Center Research

Phase 2 Completed
14 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡